Home › Trials › NCT06237803

Collection and analysis of biological samples from patients with multiple myeloma and related conditions

EMN Prospective Sample Collection Project

Observational European Myeloma Network B.V. · NCT06237803

This study is collecting and storing blood samples from patients with multiple myeloma and similar conditions to help researchers learn more about these diseases and improve treatments.

Quick facts

Study typeObservational
Enrollment6000 (estimated)
Ages18 Years and up
SexAll
SponsorEuropean Myeloma Network B.V. Research network
Locations41 sites (Melbourne and 40 other locations)
Trial IDNCT06237803 on ClinicalTrials.gov

What this trial studies

This observational study aims to establish a common international infrastructure for the prospective collection, storage, and analysis of biological samples from patients diagnosed with multiple myeloma, smoldering multiple myeloma, plasma cell leukemia, and related conditions. It will gather standard clinical variables at baseline and during treatment to facilitate future research. The study involves multiple centers across Europe and focuses on creating a comprehensive biobank for better understanding and treatment of these conditions.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with MGUS, smoldering multiple myeloma, multiple myeloma, or plasma cell leukemia.

Not a fit: Patients who have previously received anti-myeloma therapy or have had serious adverse reactions to blood donation may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of multiple myeloma and related conditions, potentially leading to improved treatment strategies.

How similar studies have performed: Other studies focusing on biobanking and observational data collection in hematological malignancies have shown success, indicating the potential for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD)
* Subjects are ≥ 18 years old.
* Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures.

  1. Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and
  2. subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements.

Exclusion Criteria:

* Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care).
* Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events.
* Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.

Where this trial is running

Melbourne and 40 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaSmoldering Multiple MyelomaPlasma Cell LeukemiaExtramedullary MyelomaMGUS
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.